Incyte Corporation: Thrombocythemia, Essential trials

The registry lists 11 Thrombocythemia, Essential studies with Incyte Corporation as lead sponsor. 4 are open to participants now and 4 have results posted.

Phase 1 6Phase 2 4Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaRecruitingNCT07623200Phase 3
• Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07008118Phase 1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
• Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)CompletedNCT02953704